Is GLUT1 a potential target for in-stent restenosis treatment?

Int J Cardiol. 2016 Nov 15:223:199-200. doi: 10.1016/j.ijcard.2016.08.071. Epub 2016 Aug 4.

Authors

Tadeusz Osadnik¹, Kamil Bujak², Andrzej Lekston³

Affiliations

¹ 2nd Department of Cardiology and Angiology, Silesian Center for Heart Diseases, Zabrze, Poland; Genomics Laboratory, Kardio-Med Silesia Science and Technology Park, Zabrze, Poland. Electronic address: tadeusz.osadnik@sccs.pl.
² Silesian Center for Heart Diseases, Zabrze, Poland.
³ 3rd Department of Cardiology, School of Medicine with the Division of Dentistry, Medical University of Silesia, Zabrze, Poland.

PMID: 27541654
DOI: 10.1016/j.ijcard.2016.08.071

No abstract available

MeSH terms

Coronary Restenosis / etiology*
Coronary Restenosis / prevention & control*
Glucose Transporter Type 1 / physiology*
Graft Occlusion, Vascular / etiology*
Graft Occlusion, Vascular / prevention & control*
Humans
Stents*

Substances

Glucose Transporter Type 1
SLC2A1 protein, human